Alzheimer’s disease therapeutics and diagnostics market will reach $8.3 billion in 2017

Wednesday 31 July 2013, Amsterdam

A new report predicts the world market for Alzheimer’s disease therapeutics and diagnostics will reach $8.3bn in 2017. That revenue forecast and others appear in Alzheimer’s Disease Therapeutics and Diagnostics: World Market 2013-2023, published in June 2013.

This report forecasts the Alzheimer’s disease (AD) therapeutics and diagnostics market will achieve strong revenue growth to 2023, especially beyond 2017. By 2017, some clinical trials will have finished and innovative products gained regulatory approval. The scope of the field is widening, with many organisations entering and collaborating.

Rodrigo Gutierrez Gamboa, a pharmaceutical industry analyst, said: “A high unmet need remains for innovative Alzheimer’s therapies that are able to alter the underlying course of this terminal disease. Several of the leading Alzheimer’s drugs have lost market exclusivity in important regions of the market, leaving the market exposed to intensified generic competition. There is also strong market need for diagnostic technologies for the early detection of AD.

“The R&D pipeline for Alzheimer’s therapies and diagnostics remains strong, with promising candidates, despite the series of high-profile failures in the late stages of clinical development. Beyond 2017, the market will be transformed by the introduction of disease-modifying therapies and innovative diagnostic technologies. The potential of new drugs and diagnostics in this market is enormous, given the high prevalence of AD and limited efficacy and utility of therapies and diagnostic tests currently available.”

This new report shows revenue forecasts to 2023 at overall world market, submarket, product and national level. Research, data and analyses cover activities of Pfizer, Eisai, Forest Laboratories, Lundbeck, Novartis and other pharmaceutical, biotechnology and diagnostics companies.

That study discusses R&D and predicts revenues to 2023 in leading national markets. The work analyses the US, Japan, Germany, France, the UK, Spain, Italy, India and China.

Alzheimer’s Disease Therapeutics and Diagnostics: World Market 2013-2023 therefore adds to our range of analytical reports on industries and markets in healthcare.